A V Global CO Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: A V Global CO Pharmaceutical Export Portfolio Dataset — 2 Products, $900.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

A V Global CO — Pharmaceutical Exporter Profile (2026) | 2 Products, $900.0K Trade | TransData Nexus

A V Global CO

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $900.0K Total Trade · DGFT Verified

A V Global CO is an Indian pharmaceutical exporter with a total trade value of $900.0K across 2 products in 2 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Codeine ($450.0K), Diphenhydramine ($450.0K), .

A V Global CO — Export Portfolio & Destination Treemap

A V Global CO pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is A V Global CO? — Company Overview & Market Position

A V Global CO is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2007, the company is headquartered in New Delhi, India. It operates as a private limited company under the Corporate Identification Number (CIN) U63090DL2007PTC159315. The authorized capital stands at ₹5.00 crore, with a paid-up capital of ₹4.00 crore. The company employs approximately 243 professionals. Its registered address is 201, New Delhi House, Barakhamba Road, New Delhi, Delhi, 110001.

What Does A V Global CO Export? — Product Portfolio Analysis

Top Products by Export Value

1Codeine$450.0K 2Diphenhydramine$450.0K

A V Global CO Therapeutic Categories — 2 Specializations

A V Global CO operates across 2 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

A V Global CO exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Codeine	Analgesics & Antipyretics	$450.0K	9	0.4%	9
2	Diphenhydramine	Antihistamines & Allergy	$450.0K	9	1.4%	10

A V Global CO exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $900.0K. The top category is Analgesics & Antipyretics (50.0% of portfolio), followed by Antihistamines & Allergy (50.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

A V Global CO — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

A V Global CO operates manufacturing facilities in India, focusing on the production of finished pharmaceutical formulations. Specific details regarding plant locations, capacities, and specializations are not publicly disclosed. The company's manufacturing processes adhere to industry standards to ensure product quality and compliance with regulatory requirements.

3Key Leadership

The leadership team of A V Global CO includes:

Ashok Kumar Mehta: Director
Vijay Mehta: Director

Both directors have been associated with the company since its inception in 2007. Their extensive experience in the pharmaceutical and logistics sectors contributes to the company's strategic direction and operational efficiency.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does A V Global CO Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

A V Global CO's export portfolio includes Codeine and Diphenhydramine, each valued at $450,000, contributing to a total export value of $900,000 across 18 shipments. These products fall under the therapeutic categories of Analgesics & Antipyretics and Antihistamines & Allergy, respectively. The company's market share in these categories is 0.4% for Codeine and 1.4% for Diphenhydramine. The top three therapeutic categories account for 50% each, indicating a balanced product portfolio. The company's portfolio concentration is high, with the top five products comprising 100% of its exports.

2Emerging Markets

A V Global CO has established a presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to countries such as Ghana, Benin, and Kenya, suggesting a strategic focus on these regions. While specific details regarding WHO prequalification are not available, the company's engagement in these markets implies efforts to meet international quality standards, facilitating access to these regions.

3Geographic Strategy

A V Global CO — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding A V Global CO's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide information on its presence in the U.S. market, suggesting limited or no direct engagement with the FDA-regulated market.

2WHO & EU GMP

Information regarding A V Global CO's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data does not indicate certifications from these international regulatory bodies, which are often essential for market access in Europe and other regions.

3CDSCO & Indian Regulatory

A V Global CO holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. The company's compliance with CDSCO regulations underscores its commitment to maintaining quality standards in its manufacturing processes.

A V Global CO — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

A V Global CO operates in the pharmaceutical export sector, focusing on finished formulations in the Analgesics & Antipyretics and Antihistamines & Allergy categories. The company's export data indicates a total export value of $900,000 across 18 shipments, with a portfolio concentration of 100% in its top five products. While specific market share data is not available, the company's strategic focus on these therapeutic categories positions it within a competitive landscape that includes both large multinational corporations and other specialized exporters.

2Key Differentiators

A V Global CO's key differentiators include its specialized focus on finished pharmaceutical formulations, particularly in the Analgesics & Antipyretics and Antihistamines & Allergy categories. The company's export strategy targeting emerging markets demonstrates its adaptability and commitment to expanding its global presence. Additionally, the absence of publicly available regulatory compliance issues reflects positively on its operational integrity.

3Strategic Position

A V Global CO's current strategic direction appears to be focused on exporting finished pharmaceutical formulations, with a particular emphasis on specific therapeutic categories. The company's engagement in emerging markets suggests a strategy aimed at diversifying its market presence and leveraging growth opportunities. Future outlooks would benefit from obtaining international certifications such as WHO prequalification and EU GMP to enhance market access and competitiveness.

Buyer Due Diligence Brief — Evaluating A V Global CO as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

A V Global CO has demonstrated a consistent track record in exporting pharmaceutical formulations, with a total export value of $900,000 across 18 shipments. The company's portfolio concentration indicates a focused approach to its product offerings. While specific reliability indicators are not publicly available, the absence of regulatory compliance issues and the company's strategic focus on emerging markets suggest a reliable and committed supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: To confirm compliance with U.S. regulations. Verification can be done through the FDA's official website.

WHO-GMP Certification: To ensure adherence to international manufacturing standards. Verification can be done through the World Health Organization's official website.

Frequently Asked Questions — A V Global CO

How many pharmaceutical products does A V Global CO export from India?

A V Global CO exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Codeine ($450.0K), Diphenhydramine ($450.0K). Total export value is $900.0K.

What is A V Global CO's total pharmaceutical export value?

A V Global CO's total pharmaceutical export value is $900.0K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does A V Global CO cover?

A V Global CO exports across 2 therapeutic categories. The largest are Analgesics & Antipyretics (50.0%, 1 products), Antihistamines & Allergy (50.0%, 1 products).

Get Full A V Global CO Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.